CN103006647B - Use of 3-amido-2-pyridone derivative - Google Patents

Use of 3-amido-2-pyridone derivative Download PDF

Info

Publication number
CN103006647B
CN103006647B CN201310000027.6A CN201310000027A CN103006647B CN 103006647 B CN103006647 B CN 103006647B CN 201310000027 A CN201310000027 A CN 201310000027A CN 103006647 B CN103006647 B CN 103006647B
Authority
CN
China
Prior art keywords
acid
add
compound
reaction
meoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310000027.6A
Other languages
Chinese (zh)
Other versions
CN103006647A (en
Inventor
周庆发
储雪平
查晓明
葛飞飞
康迪
陆涛
徐云根
张陆勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201310000027.6A priority Critical patent/CN103006647B/en
Publication of CN103006647A publication Critical patent/CN103006647A/en
Application granted granted Critical
Publication of CN103006647B publication Critical patent/CN103006647B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the field of pharmaceutical chemistry, in particular relates to a medical use of a 3-amido-2-pyridone compound, and a pharmaceutical composition containing such a compound, and especially an application as a cholinesterase inhibitor. Pharmacological experiments show such a compound has good cholinesterase inhibition activity, and has favorable application prospects in the field of treating Alzheimer disease, schizophrenia, chronic brain damage, facial paralysis, hemiplegia and the like.

Description

The purposes of one class 3-Amino-2-pyridone analog derivative
Technical field
The present invention relates to the purposes of a class 3-Amino-2-pyridone analog derivative for the preparation of medicine, be specifically related to its purposes as cholinesterase inhibitor class medicine.
Background technology
Alzheimer's disease (Alzheimer ' s disease, AD) claim that again senile dementia is a kind of disease taking chronic, carrying out property nerve degeneration as feature occurring in the geratic period, its clinical manifestation is mainly memory, cognition, language, behavior disorder and personality changes etc.Along with the arrival of aging society, its sickness rate grows with each passing day, and has now become the fourth-largest disease that causes old people's death after tumor, heart disease, cerebrovascular.
Have multiple theory about the mechanism of causing a disease of AD, wherein comparatively the cholinergic theory of main flow thinks that AD brain in patients interior neurotransmitter-acetylcholine disappearance causes AD cognitive function of patients to decline, and memory ability is lost.Use cholinesterase inhibitor to improve AD patient's choline levels, by universally recognized class of medications.In human body, there are 2 kinds of enzyme hydrolysis acetylcholine, i.e. acetylcholinesterase (AChE also claims true cholinesterase) and butyrylcholine esterase (BuChE also claims pseudocholinesterase).At present mostly be selectivity AChE inhibitor for clinical cholinesterase inhibitor, but periphery side effect is larger, long-term treatment effect is undesirable.Recently study and show, selectivity BuChE inhibitor can make extracellular acetylcholine concentration increase by 15 times, and does not find choline-like side effect.Therefore, find the double inhibitor of BuChE selective depressant or AChE and BuChE, the treatment that can be AD provides new strategy.Part 3-Amino-2-pyridone analog derivative in this patent is to the selective inhibitory action of BuChE, part 3-Amino-2-pyridone analog derivative has double inhibition effect to AChE and BuChE, the double inhibitor that is expected to become BuChE selective depressant or AChE and BuChE, has a good application prospect.
Summary of the invention
The present invention uses substituted aniline, alkynes aldehyde derivatives, diphenyl methylene glycine ethyl ester to do at NaH to react under the condition of catalyst, prepare after the 3-Amino-2-pyridone analog derivative that N replaces hydrolysis under acid condition again and obtain compound of Formula I, its reaction equation is as follows:
R in compound of Formula I 1for Ph or 3-F-C 6h 4, 3-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 2,4-2Cl-C 6h 3, 3,4-2Cl-C 6h 3, 3-F-4-Cl-C 6h 3, 4-MeOC 6h 4, 3-MeOC 6h 4, 3-NH 2c 6h 4deng the phenyl ring that contains different substituents; R 2represent Ph or 4-Me-C 6h 4, 4-MeOC 6h 4, 3,4-MeOC 6h 4, 4-Cl-C 6h 4, 3-Cl-C 6h 4, 2-Cl-C 6h 4, 4-F-C 6h 4deng the phenyl ring that contains different substituents and 2-naphthyl, 2-furanyl, Alkyl etc.
According to the present invention, pharmaceutically acceptable salt comprises the acid-addition salts that compound of Formula I and following acid form: hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-methyl benzenesulfonic acid, LOMAR PWA EINECS 246-676-2, citric acid, tartaric acid, lactic acid, acetone acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid, mandelic acid.Comprise in addition the acid salt of inorganic base, as: alkalinous metal cation, alkaline earth metal cation, ammonium cation salt contained.
General formula (I) compound is following structural compounds preferably:
3-amino-Isosorbide-5-Nitrae-diphenyl pyridin-2-ones (Ia)
3-amino-1-(3-fluorophenyl)-4-phenylpyridine-2-ketone (Ib)
3-amino-1-(3-chlorphenyl)-4-phenylpyridine-2-ketone (Ic)
3-amino-1-(4-chlorphenyl)-4-phenylpyridine-2-ketone (Id)
3-amino-1-(3-bromophenyl)-4-phenylpyridine-2-ketone (Ie)
3-amino-1-(2,4-Dichlorobenzene base)-4-phenylpyridine-2-ketone (If)
3-amino-1-(3,4-Dichlorobenzene base)-4-phenylpyridine-2-ketone (Ig)
3-amino-1-(the chloro-3-fluorophenyl of 4-)-4-phenylpyridine-2-ketone (Ih)
3z amino-1-(4-methoxyphenyl)-4-phenylpyridine-2-ketone (Ii)
3-amino-1-(3-methoxyphenyl)-4-phenylpyridine-2-ketone (Ij)
3-amino-1-(3-aminophenyl)-4-phenylpyridine-2-ketone (Ik)
3-amino-4-(4-fluorophenyl)-1-phenylpyridine-2-ketone (Il)
3-amino-4-(3-chlorphenyl)-1-phenylpyridine-2-ketone (Im)
3-amino-4-(4-aminomethyl phenyl)-1-phenylpyridine-2-ketone (In)
3-amino-4-(3-aminomethyl phenyl)-1-phenylpyridine-2-ketone (Io)
3-amino-4-(4-methoxyphenyl)-1-phenylpyridine-2-ketone (Ip)
Concrete synthesis step is:
By amine, alkynes aldehyde derivatives mixes, and reacts 30 minutes under condition of no solvent, adds diphenyl methylene glycine ethyl ester, adds anhydrous methylene chloride, after question response thing dissolves completely, adds catalyst sodium hydride, and room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains corresponding 3-Amino-2-pyridone compounds.
This reaction initiation material is easy to get, and mild condition has selected one pot of throwing method to react, and synthetic route is brief, easy to operate, and productive rate reaches more than 85%, and has saved the purge process of intermediate compound, has reduced cost.The 3-Amino-2-pyridone compounds synthetic by this method has good cholinesterase inhibition, has good application prospect in fields such as treatment Alzheimer, schizophrenia, chronic brain injury, facial paralysis, hemiplegias.
Better reaction condition of the present invention is:
(1) catalyst is sodium hydride;
(2) molar ratio of amine, alkynes aldehyde derivatives, diphenyl methylene glycine ethyl ester, sodium hydride is 1.2: 1.2: 1: 0.5;
(2) solvent is anhydrous methylene chloride;
(3) reaction temperature is room temperature.
The compounds of this invention can prepare by above-mentioned or similar above-mentioned preparation method, selects corresponding raw material according to substituent difference is different with substituting group position.
Pharmacology test result shows, compound of Formula I and pharmaceutically acceptable salt thereof all have inhibitory action in various degree to external acetylcholine esterase, therefore, compound of Formula I and pharmaceutically acceptable salt thereof can be used for the treatment of the clinical disease relevant with cholinesterase inhibitor.The described disease relevant with cholinesterase inhibitor can be Alzheimer, schizophrenia, chronic brain injury, facial paralysis, hemiplegia etc.
Part pharmacology test and result below:
[medicine and reagent]
1.AChE(500unit，E.C.3.1.1.7，Type?VI-S，from?Electric?Eel，Sigma-Aldrich)
2.BuChE(500unit，E.C.3.1.1.8，from?equine?serum，Sigma-Aldrich)
Two (2-nitrobenzoic acid) (5,5 '-Dithiobis (2-nitrobenzoic acid), DTNB, J & K Chemical) of 3.5,5 '-bis-sulfur
4. acetyl thio choline (ATC) iodide and Butyryl thiocholine (BTC) iodide (J & K Chemical)
5.DMSO(Sigma-Aldrich)
[experimental principle]
Adopt the outer cholinesterase inhibition of Ellman method test target object, experimental principle is under the buffer solution condition of pH=8, AChE and BuChE can be hydrolyzed to thiocholine by ATC and BTC respectively rapidly, thiocholine can react with DTNB fast thereupon and generate 5-sulfydryl-2-nitrobenzoyl with strong uv absorption, therefore can measure its concentration with ultraviolet spectrophotometry, and then can calculate the maximum inhibition of AChE and BuChE.
[experimental implementation]
(1) preparation buffer solution.13.6g potassium dihydrogen phosphate is dissolved in 1L water, regulates pH=8 ± 0.1 with potassium hydroxide.Be stored in 4 DEG C for subsequent use.
(2) take DTNB 10.8mg for subsequent use in 50mg centrifuge tube, take substrate A TC/BTC 3.5mg for subsequent use in 5ml centrifuge tube.
(3) preparation enzymatic solution.The AChE/BuChE of 500U/ml is dissolved in the gel solution of 1mL 1%, is then diluted with water to 100mL and makes the AChE/BuChE solution that concentration is 5U/mL, be stored in-30 DEG C for subsequent use.
(4) preparation tested material solution.Tested material is dissolved in in DMSO, to make concentration be 10 -2the mother liquor solution of M, then makes respectively the tested material solution of variable concentrations with buffer solution dilution, be stored in-30 DEG C for subsequent use.
When experiment, after being ready to, enzyme (0.25U/ml) is stored in ice chest, then dissolve preprepared DTNB (10.8mg) with 18ml buffer, after dissolving, join immediately in 96 orifice plates, every hole 160 μ l add successively enzyme after adding, every hole 50 μ l, add again the test compounds 10 μ l of respective concentration, incubate at 37 DEG C and bathe 5min.After incubating and bathing and finish, preprepared substrate A CT/BTC (3.5mg) is dissolved in 3.5ml buffer, joins fast successively that in reacting hole, (30 μ l).Under 405nm, test the ultraviolet absorptivity in 0～10min.Blank replaces tested material solution and enzymatic solution with isometric water, and negative control replaces tested material solution to record with isometric water.Measured result GraphPad Prism tM(GraphPad Software, San Diego, CA, USA) software calculates corresponding IC with non-linear decline analytical model 50value.
[experimental result]
Scheme?1.AChE?and?BuChE?Inhibition?of?Test?Compounds a，b
aData?is?the?mean?of?at?least?three?determinations. b?All?values?are?the?mean±SEM.
Pharmacologically active test result shows, the compounds of this invention has good cholinesterase inhibition, part of compounds has selectivity butyrylcholine esterase and suppresses activity and acetylcholinesterase/butyrylcholine esterase dual restraining activities, be expected to become the double inhibitor of Butyrylcholinesterasselective selective inhibitors or acetylcholinesterase/butyrylcholine esterase, wherein R 1, R 2during for larger substituted aryl compound preferably selectivity suppress butyrylcholine esterase, have a good application prospect.For the clinical disease preventing or treatment is relevant with cholinesterase inhibitor, these diseases can be: the fields such as Alzheimer, schizophrenia, chronic brain injury, facial paralysis, hemiplegia.
Detailed description of the invention
The following examples are to further illustrate of the present invention, instead of limit the scope of the invention.
Fusing point shows micro melting point apparatus mensuration by X-4 numeral, and thermometer is not proofreaied and correct; 1HNMR completes (mark in TMS) by BRUKERACF-300 type nuclear magnetic resonance analyser and BRUKERAM-500 type nuclear magnetic resonance analyser; Infrared by FTIR-8400s type fourier-transform infrared spectrophotometric device mensuration.
Embodiment 1 Compound I a's is synthetic
By aniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ia, yield 92%, mp:58-59 DEG C.IR(KBr)：v＝3449，3049，2957，2924，2850，1699，1646，1580，1520，1498，1373，1072，765，741，698cm -1. 1H?NMR(300MHz，CDCl 3)δ7.55-7.36(m，10H)，6.87(d，J＝7.0Hz，1H)，6.23(d，J＝7.1Hz，1H)，4.51(s，2H).
Synthesizing of embodiment 2 compounds ibs
By 3-fluoroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ib, yield 81%, mp:64-66 DEG C.IR(KBr)：v＝3473，3419，3345，3050，2955，2922，2850，1699，1652，1647，1637，1617，1577，1567，1561，1518，1509，1499，1459，1313，746，706. 1H?NMR(500MHz，CDCl 3)δ7.51(d，J＝17.8Hz，7H)，7.39-7.14(m，2H)，6.84(d，J＝6.2Hz，1H)，6.23(d，J＝6.0Hz，1H)，4.54(s，2H).
Embodiment 3 Compound I c's is synthetic
By 3-chloroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ic, yield 86%, mp:76-77 DEG C.IR(KBr)：v＝3460，3420，3055，1698，1644，1578，1518，1491，1374，1091，1013，826，742，699cm -1. 1H?NMR(500MHz，CDCl 3)δ7.55-7.47(m，5H)，7.44-7.36(m，4H)，6.83(d，J＝7.1Hz，1H)，6.24(d，J＝7.1Hz，1H)，4.53(s，2H).
Embodiment 4 Compound I d's is synthetic
By 4-chloroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Id, yield 97%, mp:148-149 DEG C.IR(KBr)：v＝3470，3423，3055，1699，1644，1578，1518，1491，1374，1091，1013，826，742，700cm -1. 1H?NMR(500MHz，CDCl 3)δ7.54-7.46(m，6H)，7.42-7.37(m，3H)，6.82(d，J＝7.1Hz，1H)，6.23(d，J＝7.1Hz，1H)，4.41(s，2H).
Embodiment 5 Compound I e's is synthetic
By 3-bromaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ie, yield 92%, mp:61-62 DEG C.IR(KBr)：v＝3441，3316，3060，2967，2921，2849，1699，1654，1593，1579，1570，1562，1519，1475，1375，1242，741，705cm -1. 1H?NMR(500MHz，CDCl 3)δ7.64(t，J＝1.8Hz，1H)，7.57-7.47(m，5H)，7.43-7.36(m，3H)，6.82(d，J＝7.1Hz，1H)，6.23(d，J＝7.1Hz，1H)，4.53(s，2H).
Embodiment 6 Compound I f's is synthetic
By 2; 4-dichloroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely, add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid If, yield 95%, mp:197-198 DEG C.IR(KBr)：v＝3459，3429，3347，3315，3056，3029，2923，2851，1699，1647，1610，1581，1570，1561，1518，1477，1376，1317，1099，804，766，701.1 H?NMR(500MHz，CDCl 3)δ7.59(d，J＝1.1Hz，1H)，7.56-7.48(m，4H)，7.41-7.34(m，3H)，6.65(d，J＝7.1Hz，1H)，6.25(d，J＝7.1Hz，1H)，4.51(s，2H).
Embodiment 7 Compound I g's is synthetic
By 3; 4-dichloroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely, add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ig, yield 94%, mp:124-125 DEG C.IR(KBr)：v＝3433，3331，3069，2925，2851，1699，1654，1579，1519，1475，1391，1365，1308，1030，834，754，699. 1H?NMR(500MHz，CDCl 3)δ7.61(d，J＝2.2Hz，1H)，7.58(d，J＝8.5Hz，1H)，7.53-7.48(m，4H)，7.39(t，J＝7.0Hz，1H)，7.35(dd，J＝8.5，2.4Hz，1H)，6.80(d，J＝7.1Hz，1H)，6.24(d，J＝7.2Hz，1H)，4.32(s，2H).
Embodiment 8 Compound I h's is synthetic
By chloro-4-3-fluoroaniline (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ih, yield 82%, mp:146-147 DEG C.IR(KBr)：v＝3435，3081，2925，1701，1654，1647，1636，1625，1617，1611，1559，1519，1068，755，696. 1H?NMR(500MHz，CDCl 3)δ7.55-7.48(m，5H)，7.39(t，J＝7.1Hz，1H)，7.34(dd，J＝9.4，2.3Hz，1H)，7.23(d，J＝8.4Hz，1H)，6.81(d，J＝7.2Hz，1H)，6.24(d，J＝7.2Hz，1H).4.53(s，2H).
Embodiment 9 Compound I i's is synthetic
By 4-aminoanisole (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ii, yield 95%, mp:177-178 DEG C.IR(KBr)：v＝3466，3422，3349，3307，3054，2962，2920，2841，1703，1645，1639，1562，1510，1440，1247，1026，830，748，697. 1H?NMR(500MHz，CDCl 3)δ7.55-7.47(m，4H)，7.39-7.34(m，3H)，7.02-6.99(m，2H)，6.84(d，J＝7.1Hz，1H)，6.20(d，J＝7.1Hz，1H)，4.52(s，1H)，3.86(s，3H).
Embodiment 10 Compound I j's is synthetic
By 3-aminoanisole (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ij, yield 96%, mp:65-66 DEG C.IR(KBr)：v＝3293，3064，2839，1698，1683，1653，1578，1560，1491，1457，1324，1034，769，739，702. 1H?NMR(500MHz，CDCl 3)δ7.54(d，J＝7.6Hz，2H)，7.49(t，J＝7.7Hz，2H)，7.41-7.36(m，2H)，7.04-6.95(m，3H)，6.86(d，J＝7.1Hz，1H)，6.21(d，J＝7.1Hz，1H)，4.53(s，2H)，3.85(s，3H).
Embodiment 11 Compound I k's is synthetic
By 1; 3-o-phenylenediamine (0.6mmol); 3-phenyl acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely, add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ik, yield 80%, mp:163-164 DEG C.IR(KBr)：v＝3412，3416，3347，3080，3052，2922，2851，1699，1651，1637，1578，1560，1519，1507，1460，1314，746，706. 1H?NMR(500MHz，CDCl 3)δ7.54(d，J＝7.3Hz，2H)，7.49(t，J＝7.6Hz，2H)，7.38(t，J＝7.3Hz，1H)，7.25-7.22(m，1H)，7.18-7.13(m，1H)，6.88(t，J＝7.0Hz，2H)，6.81(d，J＝7.1Hz，1H)，6.26(d，J＝7.1Hz，1H)，4.54(s，2H)，3.90(s，2H).
Embodiment 12 Compound I l's is synthetic
By aniline (0.6mmol); 3-(4-fluorophenyl)-acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Il, yield 97%, mp:61-62 DEG C.IR(KBr)：v＝3448，3408，3289，3064，2923，2848，1683，1645，1594，1575，1508，1454，1218，1157，840，752，694. 1H?NMR(500MHz，CDCl 3)δ7.54-7.49(m，4H)，7.45-7.41(m，3H)，7.20-7.16m，2H)，6.86(d，J＝7.1Hz，1H)，6.18(d，J＝7.1Hz，1H)，4.39(s，2H).
Embodiment 13 Compound I m's is synthetic
By aniline (0.6mmol); 3-(3-chlorphenyl)-acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Im, yield 95%, mp:55-56 DEG C.IR(KBr)：v＝3418，3307，3074，2917，2848，1700，1654，1649，1609，1576，1559，1521，1513，1507，1496，1456，1359，1298，1247，779，768. 1H?NMR(500MHz，CDCl 3)δ7.53-7.49(m，3H)，7.45-7.41(m，5H)，7.37-7.35(m，1H)，6.86(d，J＝7.1Hz，1H)，6.18(d，J＝7.1Hz，1H)，4.55(s，2H).
Embodiment 14 Compound I n's is synthetic
By aniline (0.6mmol); 3-(4-aminomethyl phenyl)-acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Im, yield 98%, mp:77-78 DEG C.IR(KBr)：v＝3307，3055，2963，2923，2841，1699，1646，1639，1617，1582，1570，1561，1509，1499，1442，1293，1247，1026，830，748，697. 1H?NMR(500MHz，CDCl 3)δ7.51-7.40(m，7H)，7.30(d，J＝7.9Hz，2H)，6.85(d，J＝7.1Hz，1H)，6.21(d，J＝7.1Hz，1H)，4.46(s，2H)，2.41(s，3H).
Embodiment 15 Compound I o's is synthetic
By aniline (0.6mmol); 3-(3-aminomethyl phenyl)-acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Io, yield 97%, mp:50-51 DEG C.IR(KBr)：v＝3448，3074，2917，2848，1685，1654，1648，1637，1576，1522，1496，1260，777，760，696. 1H?NMR(500MHz，CDCl 3)δ7.50(t，J＝7.7Hz，2H)，7.46-7.40(m，3H)，7.39-7.32(m，3H)，7.19(d，J＝7.3Hz，1H)，6.85(d，J＝7.1Hz，1H)，6.21(d，J＝7.1Hz，1H)，4.50(s，2H)，2.42(s，3H).
Embodiment 16 Compound I p's is synthetic
By aniline (0.6mmol); 3-(4-methoxyphenyl)-acraldehyde (0.6mmol) mixes; under nitrogen protection, under condition of no solvent, react 30 minutes; add diphenyl methylene glycine ethyl ester (0.5mmol); after adding solvent anhydrous methylene chloride question response thing to dissolve completely; add catalyst sodium hydride, room temperature reaction is substantially complete to reaction.Add the 0.5mol/L HCl reaction that is hydrolyzed, after reacting completely, add saturated sodium bicarbonate solution cancellation, ethyl acetate extraction, column chromatography obtains white solid Ip, yield 98%, mp:67-68 DEG C.IR(KBr)：v＝3453，3051，2956，2918，2849，1699，1647，1610，1579，1513，1465，1253，1173，1026，830，753，694. 1H?NMR(500MHz，CDCl 3)δ7.51-7.46(m，4H)，7.45-7.40(m，3H)，7.02(d，J＝8.5Hz，2H)，6.85(d，J＝7.1Hz，1H)，6.20(d，J＝7.1Hz，1H)，4.43(s，2H)，3.86(s，3H)。

Claims (3)

1. following general formula I compound and its pharmaceutically acceptable salt, and the purposes of the pharmaceutical composition that contains compound of Formula I and its pharmaceutically acceptable salt in the medicine for the preparation of prevention or the treatment disease relevant with cholinesterase inhibitor:
R 1for Ph or 3-F-C 6h 4, 3-Cl-C 6h 4, 4-Cl-C 6h 4, 3-Br-C 6h 4, 2,4-2Cl-C 6h 3, 3,4-2Cl-C 6h 3, 3-F-4-Cl-C 6h 3, 4-MeOC 6h 4, 3-MeOC 6h 4, 3-NH2C 6h 4;
R 2for Ph or 4-Me-C 6h 4, 4-MeOC 6h 4, 4-Cl-C 6h 4, 4-F-C 6h 4.
2. purposes according to claim 1, wherein pharmaceutically acceptable salt is selected from the acid-addition salts of compound of Formula I and following acid formation: hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, p-methyl benzenesulfonic acid, LOMAR PWA EINECS 246-676-2, citric acid, tartaric acid, lactic acid, acetone acid, acetic acid, maleic acid or benzenesulfonic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.
3. purposes according to claim 1, wherein the disease relevant with cholinesterase inhibitor is Alzheimer, schizophrenia, chronic brain injury, facial paralysis, hemiplegia.
CN201310000027.6A 2013-01-04 2013-01-04 Use of 3-amido-2-pyridone derivative Expired - Fee Related CN103006647B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310000027.6A CN103006647B (en) 2013-01-04 2013-01-04 Use of 3-amido-2-pyridone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310000027.6A CN103006647B (en) 2013-01-04 2013-01-04 Use of 3-amido-2-pyridone derivative

Publications (2)

Publication Number Publication Date
CN103006647A CN103006647A (en) 2013-04-03
CN103006647B true CN103006647B (en) 2014-09-10

Family

ID=47956113

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310000027.6A Expired - Fee Related CN103006647B (en) 2013-01-04 2013-01-04 Use of 3-amido-2-pyridone derivative

Country Status (1)

Country Link
CN (1) CN103006647B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255134A (en) * 2008-04-08 2008-09-03 温州医学院 Aryl pyridine compounds and medicament uses thereof
CN101440061A (en) * 2008-04-08 2009-05-27 温州医学院 Arylpyridone derivatives with acetylcholine esterase inhibition activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255134A (en) * 2008-04-08 2008-09-03 温州医学院 Aryl pyridine compounds and medicament uses thereof
CN101440061A (en) * 2008-04-08 2009-05-27 温州医学院 Arylpyridone derivatives with acetylcholine esterase inhibition activity

Also Published As

Publication number Publication date
CN103006647A (en) 2013-04-03

Similar Documents

Publication Publication Date Title
ES2774510T3 (en) 1,3,4-Oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitors and pharmaceutical composition comprising the same
US20210032207A1 (en) Quinolone compound
Lan et al. Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer’s disease
Knez et al. Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents
CZ2004634A3 (en) Quinoline compound, process for its preparation and pharmaceutical composition in which the compound is comprised
Derabli et al. A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives
CA2400368A1 (en) Catechol diethers as selective pde iv inhibitors
CA2763960C (en) Bicyclic and tricyclic compounds as kat ii inhibitors
Hamdani et al. Synthesis, crystal structures, computational studies and α-amylase inhibition of three novel 1, 3, 4-oxadiazole derivatives
Abdullah et al. Design, synthesis, molecular docking, anti-Proteus mirabilis and urease inhibition of new fluoroquinolone carboxylic acid derivatives
Ozadali-Sari et al. Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl) phenyl] benzimidazoles
Le-Nhat-Thuy et al. Synthesis and biological evaluation of novel quinazoline-triazole hybrid compounds with potential use in Alzheimer’s disease
BRPI0616452B1 (en) quinolines and their therapeutic use
JPH06500794A (en) Heterocyclic-cyclic amine derivatives
JPH04312584A (en) Aryl (or heteroaryl) piperazinylalkylazole derivatives, method of manufacturing same and use thereof for medicinal use
Bhagat et al. Novel series of triazole containing coumarin and isatin based hybrid molecules as acetylcholinesterase inhibitors
CN105524043B (en) Lactams histon deacetylase (HDAC) inhibitor
Bajda et al. Novel carbamate derivatives as selective butyrylcholinesterase inhibitors
CN111410659A (en) PDE9 inhibitors and uses thereof
Ullah et al. Synthesis of substituted benzohydrazide derivatives: In vitro urease activities and their molecular docking studies
Pashaei et al. Synthesis and molecular dynamic simulation studies of novel N-(1-benzylpiperidin-4-yl) quinoline-4-carboxamides as potential acetylcholinesterase inhibitors
Shatsauskas et al. Synthesis of benzo [c][1, 7] naphthyridine derivatives
CN103006647B (en) Use of 3-amido-2-pyridone derivative
KR101679262B1 (en) 4-Isopropylchroman-3-ol derivatives
Muscia et al. Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20180104